Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations

Wen Shuo Wu, Yuh Min Chen, Chun Ming Tsai, Jen Fu Shih, Chao Hua Chiu, Kun Ta Chou, Shinn Liang Lai, Chieh Hung Wu, Yung Hung Luo, Chu Yun Huang, Yu Chin Lee, Reury Perng Perng, Jacqueline Whang-Peng

Research output: Contribution to journalArticlepeer-review

19 Citations (Scopus)

Fingerprint Dive into the research topics of 'Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations'. Together they form a unique fingerprint.

Medicine & Life Sciences